2021 Volume 54 Issue 2 Pages 61-68
[Introduction]We evaluated the efficacy of lubiprostone and linaclotide against chronic constipation in hemodialysis(HD)patients at a long‒term care hospital.[Subjects]Twenty‒five HD patients with chronic constipation were enrolled in this study.[Methods]The patients were prescribed sennoside for 1 month. At the start of the study, the sennoside was changed to lubiprostone. After 1 month, lubiprostone was changed to sennoside once again. Then, 1 month later, the sennoside was changed to linaclotide.[Results]The non‒diabetic kidney disease group exhibited significantly lower serum inorganic phosphorus levels after 1 month’s lubiprostone therapy than at the initiation of the treatment. In addition, their Constipation Scoring System scores were significantly lower after 1 month’s linaclotide therapy than at the initiation of the treatment. However, in the diabetic kidney disease group, neither lubiprostone nor linaclotide caused any improvements.[Conclusion]It is postulated that lubiprostone and linaclotide are useful treatments for chronic constipation in HD patients with non‒diabetic kidney disease at long‒term care hospitals.